Pinned Tweet
Recent colonoscopy from this past week (still in remission for Crohn's)...comments welcome
2
Mild cramping from past couple days of eating too well! So worth it and back to normal diet this week and extra sleep!
17
Randomly started to have cramping tonight, which I haven’t felt in many many months! Overall feeling amazing though
27
A new chapter begins for "Gut Check"! 🎙️
In this episode, we're saying farewell to longtime hosts Drs. Sam Eisenstein and Biddy Das and welcoming Drs. Irlna Tantchou and Pavel Mazirka as they take the mic.
Join us as we reflect on memorable moments, share a few laughs, and look ahead to what's next for "Gut Check."
🔗 bit.ly/3YzjpvG
@PubMEG
Crohn's Zone retweeted
Great couple of slides lining up the IL23 agents in UC. @ucsfibd @bruce_sands1
The 21st annual @ucsfibd conference kicks off with @bruce_sands1 and a state of the art lecture on UC. So how can appendectomy be both a risk factor for extension of proctitis AND a possible treatment? Interesting.
Crohn's Zone retweeted
🚨 Exciting news in Crohn’s disease care!
FDA approves subcutaneous SKYRIZI induction, offering patients greater flexibility and convenience.
A welcome step toward making effective IBD treatment fit patients’ lives!
#IBD #CrohnsDisease #IBDLibrary
linkedin.com/posts/ibd-crohn…
Crohn's Zone retweeted
❗ The #FDA expanded @abbvie’s #Skyrizi approval for adults with moderately to severely active #CrohnsDisease, allowing subcutaneous induction doses.
Data from AFFIRM showed improved clinical remission at week 12 compared with placebo. vist.ly/5prgv
Crohn's Zone retweeted
Skyrizi OBI induction now FDA approved!! news.abbvie.com/2026-10-23-U…
#IBD @MRegueiroMD @DCharabaty @ibdgijami @JosephHabibi_MD @EdwardLoftus2 @IBD_FloMD
Crohn's Zone retweeted
Amazing experience for our IBD team @MayoClinicGIHep AZ with world renowned IUS guru Dr Christian Maaser as our visiting professor. Thanks @silverman_anna @MKaur_MD for setting up the workshop for the fellows! @BowelUltrasound
Crohn's Zone retweeted
What a moment for the IBD community! 💜
Auburn University kicker Alex McPherson hit a 34-yard game-winning field goal as time expired to beat Georgia, the top-ranked team in the country, 27-24 last Saturday. Two years ago, ulcerative colitis kept him off the field for nearly the entire season. Alex has shared his journey living with IBD and an ostomy, and now he’s showing everyone what’s possible.
Congratulations, Alex! You’re an inspiration to everyone living with Crohn’s disease and ulcerative colitis. 🏈 bit.ly/4ibPYJc
Crohn's Zone retweeted
The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
The approval is based on results from the ATOMIC clinical trial led by Mayo Clinic. Learn more: mayocl.in/4yfvUM2
Crohn's Zone retweeted
Prof Florian Rieder: (OP-003) PALI-2108 (PDE4 inhibitor) for fibrostenosing Crohn’s was safe and possibly effective (n=5) with favorable PK and target engagement #uegweek2026
Crohn's Zone retweeted
Earlier this week I said the most important development in IBD of the last decade was... biosimilars.
Here's the other half of the story.
20 new molecules in Phase 2 or later. Eight targets, plus dual-target combinations. If their trials succeed, up to six could be approved in Europe by 2031.
TL1A is entering phase 3 readout time. Oral IL-23R blockade is in Phase 3. Co-formulated combination therapy is in Phase 3.
Look at phase 2 and the pipeline is stacked. There’s even an anti-fibrotic for stricturing Crohn's.
Biosimilars bought the headroom. This is what fills it. And it is very exciting.
The limiting step now isn't the science. It's trial delivery: opening sites, finding eligible patients, research teams fitting studies around full clinical jobs.
The good news? That's the part we can fix. Faster set-up, and every eligible patient offered a trial. That's how 2033 becomes 2031.
Honestly, this is extraordinary.
Crohn's Zone retweeted
A potential new option for one of Crohn’s disease’s toughest complications.
New phase 3 FUZION data explored guselkumab for perianal fistulizing Crohn’s disease—with results that GEN Expert Pick Uma Mahadevan, MD, called notable: gastroendonews.com/a/iz0BAA/… #IBD
Crohn's Zone retweeted
Very timely discussion on @mondaynightibd.
Exciting new monoclonal antibodies are getting closer to entering the IBD treatment armamentarium: anti TL1A therapies.
Several molecules are now competing in this race, with subtle but potentially important molecular differences in how they interact with TL1A and the TL1A DR3 pathway.
So far, I would not call the efficacy results earthshattering. The bigger questions may be what makes this pathway truly different:
🔬 Can TL1A inhibition make a clinically meaningful dent in intestinal fibrosis, rather than simply control inflammation?
🧬 Could its future lie in combination therapy, as Spyre is exploring by combining TL1A blockade with other pathways?
And one question I find particularly intriguing:
💭 Could TL1A inhibition eventually have a role in collagenous colitis, given the biology of mucosal inflammation and collagen deposition?
The TL1A story may ultimately be less about another effective biologic and more about whether it can do something our current therapies cannot.
Check out my LinkedIn post
linkedin.com/posts/ibd-libra…
#IBD #CrohnsDisease #UlcerativeColitis #TL1A
@MondayNightIBD @DCharabaty @Bealoquebea @IBDimmunology @ShomronH @RPanaccione
Replying to @DCharabaty @MondayNightIBD @sanofi @vipuljairath @PeyrinBiroulet @silvio_silvio75 @doc_ibd @MSHS_IBDCenter @DrJessicaA @AndresYarur @AdamEhrlichMD @AdamFayeMD @Badr_AlBawardy @ShomronH @BenClickMD @BrunoSilva_MD @Dana_Lukin @dr_fcalderaibd @KerbageAnthony @pdxIBD @DisneyBen @UKGastroDr @joshsteinbergMD @DSTEINGIMD @DrMohdZein @DiscoverIBD @EdwardLoftus2 @EdBarnesMD @FITWITMD @fudmanMD @GuiRamosMD @GastroHealthDoc @GauravsyalMD @HorstIBDDoc @SaraElOualiMD @ibdtweets @IBDimmunology @ibdgijami @ibdnaik @ibdseb @JHashashMD @KralJan @Bealoquebea @ign76 @P_DeepakIBDMD @CiorbaGI @PatricioIbanez @KaazanPatricia @NEJM @RajaAtreya @ReezwanaCMD
18/ #MondayNightIBD
🔥Anti-TL1A-Exciting 🆕 MOA
🧘🏽♀️RELIEVE-UCCD/DUVA
🏹ARTEMIS-UC & 🎻APPOLO-CD/TULI
🌻TUSCANY(UC)/AFIM
✅Meaningful induction efficacy
✅Efficacy maintained at 1yr
✅👌🏽 Safety, no class 🚩
✅Low immunogenicity
💬What are you mostly excited about for this MOA?
Crohn's Zone retweeted
This thread is a great summary of what we know so far for the anti-TL1A antibodies for the treatment of #IBD
Once we see the phase 3 data on these molecules we’ll have a better sense of how they fit in the algorithm
Replying to @DCharabaty @MondayNightIBD @sanofi @vipuljairath @PeyrinBiroulet @silvio_silvio75 @doc_ibd @MSHS_IBDCenter @DrJessicaA @AndresYarur @AdamEhrlichMD @AdamFayeMD @Badr_AlBawardy @ShomronH @BenClickMD @BrunoSilva_MD @Dana_Lukin @dr_fcalderaibd @KerbageAnthony @pdxIBD @DisneyBen @UKGastroDr @joshsteinbergMD @DSTEINGIMD @DrMohdZein @DiscoverIBD @EdwardLoftus2 @EdBarnesMD @FITWITMD @fudmanMD
5/#MondayNightIBD
RELIEVE UCCD 📊Wk 14 outcomes in #Crohns
🔦Endo Response (≥50% ↓ SES-CD)
48% (900mg)/ 26% (450mg) DUVA vs 13% PBO
Δ33% PP >0.99 | Δ13% PP 0.94
🩺Clinical Remission (PRO2)
37%/37% DUVA vs 26% PBO
Δ10% PP 0.87 (both doses)
Crohn's Zone retweeted
Important messages by @berinsj during @AmCollegeGastro Midwest PG Course. 6 Principles of acute severe ulcerative colitis management.
🕯️Colectomy rate is still bothersome in ASUC
🕯️JAKi may help produce a meaningful dent in colectomy rate
🕯️Never forget to address mental health early
Patient education is critical



































